Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

What Is Gonorrhea? What Causes Gonorrhea?
Gonorrhea (from Late Latin gonorrhoia where gonos means "seed" and rhoe means "flow") is a sexually transmitted bacterial infection that tends to attack the mucous membranes of the body. It is the second most common sexually transmitted disease in the U.S.; the first being Chlamydia. The bacteria reside in the warm and moist body cavities of both men and women and are highly contagious. Gonorrhea is the most common cause of female infertility and is also known as "the clap" or "the drip". Only a fraction of women infected with the disease show any symptoms, leaving them unaware of their condition. If left untreated, gonorrhea patients can develop pelvic inflammatory disease or PID (women), or an inflammation of the epididymis, prostate gland, or urethral structure (men), all of which are far more difficult to treat.
generic viagra online
Brain Irradiation In Lung Cancer
A national Radiation Therapy Oncology Group (RTOG) study led by a Medical College of Wisconsin Cancer Center physician at Froedtert Hospital in Milwaukee has found that a course of radiation therapy to the brain after treatment for locally advanced non-small cell lung cancer reduced the risk of metastases to the brain within the first year after treatment. The study was presented at the American Society of Clinical Oncology annual meeting in Orlando, June 1.
News of the day
New Internet Intervention Gives Insomnia Patients A Better Night's Sleep
The estimated one-third of adults who suffer from insomnia could soon find effective treatment without ever leaving their homes. Researchers at the University of Virginia Health System have developed a unique Internet-based intervention, based on well-established face-to-face cognitive behavioral therapy techniques, that has shown remarkable results in improving patients" sleep.
Public Health

ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented At ASCO

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced the presentation of encouraging trastuzumab-DM1 (T-DM1) clinical data at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Orlando, Florida. T-DM1, an antibody-drug conjugate, consists of ImmunoGen"s DM1 cancer-cell killing agent linked to the HER2-targeted antibody, trastuzumab, developed by Genentech, Inc. (a wholly-owned member of the Roche Group). Genentech (US) and Roche (ex-US) are conducting a broad clinical program with T-DM1 in HER2-positive breast cancer. "These findings are particularly impressive because of the number of patients with advanced breast cancer who responded to treatment with T-DM1, the duration of their response, and the tolerability profile reported," commented Daniel Junius, President and Chief Executive Officer. "We developed our Targeted Antibody Payload, or TAP, technology to achieve highly effective, well-tolerated cancer treatments, and are very encouraged by the results reported." Today"s presentation, "A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): final results" (abstract #1017), features updated data from the first T-DM1 Phase II trial. This non-pivotal trial evaluated T-DM1 in patients with HER2-positive MBC that had progressed on a regimen containing trastuzumab (Herceptin®). Sixty percent of the 112 study patients also had been treated with a regimen containing lapatinib (Tykerb®). Among the findings presented were: - 25 percent of patients had a confirmed objective response as assessed by an independent review facility (IRF), the primary endpoint of the study. Among these 28 patients, 22 were still receiving T-DM1 at the time of data cut-off for presentation; - 35 percent of patients had clinical benefit by IRF that consisted of either a confirmed objective response or stable disease lasting for at least 6 months; and - The anti-tumor activity seen in patients who had received lapatinib as well as trastuzumab was similar to that seen in the overall study population. Among the 75 efficacy-evaluable patients who were verified to be HER2-positive by a central laboratory: - 32 percent had a confirmed objective response by IRF; and - 44 percent had clinical benefit by IRF consisting of either a confirmed objective response or stable disease lasting for at least 6 months. The most common severe (Grade 3 or 4) adverse events were hypokalemia (lowered potassium levels) in 8 percent of patients and thrombocytopenia (lowered platelet levels) in 7 percent of patients. No severe (Grade 3 or 4) cardiac-specific toxicity was observed. One patient died during the study due to disease progression, unrelated to treatment with T-DM1. In February 2009, Genentech and Roche initiated the global Phase III EMILIA study evaluating T-DM1 for second-line treatment of advanced HER2-positive breast cancer. Additionally, Genentech recently completed patient enrollment in a Phase II study evaluating T-DM1 for third-line treatment of advanced HER2-positive breast cancer. Genentech has stated that, if the data from this study are compelling, it will discuss an earlier approval path with the US Food and Drug Administration (FDA). ImmunoGen, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009